OncoMatch/Clinical Trials/NCT06647940
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Is NCT06647940 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Orelabrutinib Oral Tablet and R-CHOP Protocol for diffuse large b cell lymphoma (dlbcl).
Treatment: Orelabrutinib Oral Tablet · R-CHOP Protocol — This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 overexpression
CD5-positive DLBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: btk inhibitor
Lab requirements
Blood counts
sufficient bone marrow function
Kidney function
sufficient kidney function
Liver function
sufficient liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify